RTW Bio's Avere To Merge With NextCure
RTW Biotech Opportunities said its portfolio company Avere Therapeutics will merge with NextCure Inc. in an all-stock deal expected to close by year-end. The combined firm will trade on Nasdaq as Avere Therapeutics under AVRX. Avere plans $820M in private placements, including $5.9M from Avere, to fund AVR-001 Phase 2b psoriasis, Phase 3 psoriasis, and Phase 2b ulcerative colitis.
How this was made
The 30-second read
Why it matters
The deal combines a corporate restructuring (reverse-merger style) with a sizable $820 million private financing intended to fund psoriasis and ulcerative colitis clinical milestones, creating near-term valuation and execution risk for both NXTC and the post-merger AVRX vehicle.
Market read
Traders can reassess deal probability, expected dilution, and the funding runway for psoriasis Phase 2b/3 and ulcerative colitis Phase 2b based on the announced merger and $820 million financing.
What to watch
No exchange ratio, ownership percentages, or detailed closing conditions are provided; traders may need to wait for definitive merger documentation to assess dilution, voting outcomes, and regulatory or financing contingencies.
Background
Avere Therapeutics, a private portfolio company of RTW Biotech Opportunities, agreed to merge with NextCure in an all-stock transaction, with the combined entity set to trade on Nasdaq as Avere Therapeutics.
Ticker impact
NextCure agreed to merge with Avere in an all-stock deal expected to close by year-end, shifting its corporate path and capital plan.
Elevated volatility around deal mechanics and financing; direction depends on perceived dilution and probability of closing.
The article discloses an all-stock merger, year-end close expectation, and a new combined-company trading plan, which typically impacts valuation and risk premium even without explicit exchange ratios.
Market effects
Biotech reverse-merger and financing activity signals continued capital formation for psoriasis programs, potentially supporting sentiment toward small-cap clinical-stage names.
US Nasdaq listing for the combined entity may shift liquidity and investor base from private/foreign exposure to US biotech traders.
Cross-border portfolio exposure (RTW.L) highlights ongoing global capital flows into late-stage dermatology pipelines via M&A structures.
Counterpoint
The all-stock structure and large private placements can be dilution-heavy; the market may discount the deal if financing terms imply weaker economics than implied by clinical plans.
Key entities
- private companyAvere Therapeutics
Agreed to merge with NextCure and will raise $820 million via private placements to fund psoriasis and ulcerative colitis programs.
- public companyNextCure Inc.
Counterparty in the all-stock merger; its shareholders face deal execution and dilution risk.
- public companyRTW Biotech Opportunities Ltd.
Holds a small NAV exposure to Avere (0.3% as of June 30) and will participate in the placements.
- ticker/vehicleAVRX
Nasdaq trading ticker for the combined company operating as Avere Therapeutics post-merger.
